Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 11/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 11/20 | 1.00 |
| ▸ | CHRNB4 | P30926 | 8/20 | 0.66 |
| ▸ | CHRNA3 | P32297 | 8/20 | 0.66 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.66 |
| ▸ | CHRNG | P07510 | 2/20 | 0.66 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.66 |
| ▸ | CHRND | Q07001 | 2/20 | 0.66 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4415997 | 0.98 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL4404495 | 0.80 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL14198968 | 0.79 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Hydrochloric Acid SCHEMBL4413197 | 0.78 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL4406591 | 0.74 | CHRNB2 (0.59) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL18682061 | 0.73 | CHRNB2 (0.57) | CHRNB2CHRNA4 | |
| SCHEMBL5768474 | 0.70 | CHRNB2 (0.82) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL4406586 | 0.70 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL4406668 | 0.70 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL531907 | 0.69 | CYP1A2 (0.55) | CHRNB2CHRNA4HTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1619192-B1 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PROD INC (US) | 2009-12-30 | — | — | EP | claimed |
| US-7205300-B2 | Aryl fused azapolycyclic compounds | PFIZER INC (US) | 2007-04-17 | — | — | US | claimed |
| US-7144882-B2 | Aryl fused azapolycyclic compounds | PFIZER INC (US) | 2006-12-05 | — | — | US | claimed |
| EP-1259489-B1 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PROD INC (US) | 2006-06-07 | — | — | EP | claimed |
| US-20050215571-A1 | Therapeutic combination for cognititon enhancement and psychotic disorders | PFIZER INC. | 2005-09-29 | — | — | US | claimed |
| US-20030130260-A1 | Aryl fused azapolycyclic compounds | COE JOTHAM WADSWORTH (US) | 2003-07-10 | — | — | US | claimed |
| EP-1619192-B1 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PROD INC (US) | 2009-12-30 | — | — | EP | disclosed |
| US-7205300-B2 | Aryl fused azapolycyclic compounds | PFIZER INC (US) | 2007-04-17 | — | — | US | disclosed |
| US-7144882-B2 | Aryl fused azapolycyclic compounds | PFIZER INC (US) | 2006-12-05 | — | — | US | disclosed |
| EP-1259489-B1 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PROD INC (US) | 2006-06-07 | — | — | EP | disclosed |
| EP-1619192-A2 | Aryl fused azapolycyclic compounds | Pfizer Products Inc. (US) | 2006-01-25 | — | — | EP | disclosed |
| US-20050215571-A1 | Therapeutic combination for cognititon enhancement and psychotic disorders | PFIZER INC. | 2005-09-29 | — | — | US | disclosed |
| US-6605610-B1 | Reducing nicotine addiction; treating neurological and psychological disorders | PFIZER INC | 2003-08-12 | — | — | US | disclosed |
| US-20030130260-A1 | Aryl fused azapolycyclic compounds | COE JOTHAM WADSWORTH (US) | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215571-A1 | Therapeutic combination for cognititon enhancement and psychotic disorders | CHRNA3, CHRNA7, CHRNA2 | CHRNB2 11/4885CHRNA4 6/4885CHRNB4 13/4885 |
| US-20030130260-A1 | Aryl fused azapolycyclic compounds | GRIN2C, GRIN2A, GRIN3A | CHRNB2 297/4885CHRNA4 236/4885CHRNB4 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.